— Know what they know.
Not Investment Advice

CRMD

CorMedix Inc.
1W: +3.8% 1M: -6.5% 3M: -46.6% YTD: -45.6% 1Y: -38.6% 3Y: +93.3% 5Y: -31.1%
$6.61
+0.15 (+2.32%)
After Hours: $6.48 (-0.13, -1.97%)
NASDAQ · Healthcare · Biotechnology · $522.5M · Alpha Radar Sell · Power 42
Smart Money Score
Bullish 75
Insider+$0.3M
Congress
ETF Holdings
Key Statistics
Market Cap$522.5M
52W Range5.6-17.43
Volume883,286
Avg Volume2,592,696
Beta1.42
Dividend
Analyst Ratings
6 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOJoseph Todisco
Employees64
SectorHealthcare
IndustryBiotechnology
IPO Date2010-05-13
300 Connell Drive
Berkeley Heights, NJ 07922
US
908 517 9500
About CorMedix Inc.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Recent Insider Trades

NameTypeSharesPriceDate
Zelnick Kaufman Beth A-Award 36,006 2026-02-04
Hurlburt Elizabeth A-Award 36,006 2026-02-04
Todisco Joseph A-Award 77,156 2026-02-04
Kaplan Myron A-Award 30,453 2026-01-26
Dillione Janet A-Award 30,453 2026-01-26

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms